Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Cardiac Safety in Patients With HER2 Positive Early Breast Cancer Treated With Herceptin
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3942
- Registration Number
- NCT01152606
- Locations
- 🇦🇹
Lkh-Univ. Klinikum Graz; Klinik Für Gynäkologie, Graz, Austria
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇦🇹LKH Hochsteiermark; Abt. für Innere Medizin, Leoben, Austria
A Study of RO4989991 in Patients With Allergic Rhinitis
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: RO4989991Drug: Placebo
- First Posted Date
- 2010-06-29
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT01152619
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 145
- Registration Number
- NCT01149057
A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer, Ovarian Cancer
- Interventions
- Drug: RO5323441
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT01148758
A Study of MabThera (Rituximab) in Elderly Patients With Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 234
- Registration Number
- NCT01144364
- Locations
- 🇮🇹
Dept. Medicina Clinica E Sperimentale; Sez. Medicina Interna E Scienze Oncologiche - Pol. Monteluce, Perugia, Umbria, Italy
🇮🇹ASST PAPA GIOVANNI XXIII; Ematologia, Bergamo, Lombardia, Italy
🇮🇹Ospedale S. Eugenio; Divisione Di Ematologia, Roma, Lazio, Italy
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
Phase 2
Terminated
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT01144403
A Study of RO5212054 (PLX3603) in Participants With BRAF V600-Mutated Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- Drug: RO5212054
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT01143753
- Locations
- 🇦🇺
Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia
🇪🇸Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
🇩🇰Rigshospitalet, Onkologisk Klinik, København Ø, Denmark
A Study of RO5045337 in Patients With Liposarcomas Prior to Debulking Surgery
Phase 1
Completed
- Conditions
- Sarcoma
- Interventions
- Drug: RO5045337
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT01143740
A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- Drug: BevacizumabDrug: DocetaxelDrug: TrastuzumabProcedure: SurgeryRadiation: RadiotherapyDrug: Hormonal Therapy
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT01142778
- Locations
- 🇫🇷
Centre Leon Berard; Oncologie Genetique, Lyon, France
🇫🇷Centre D'Oncologie de Gentilly; Oncology, Nancy, France
🇫🇷Centre Radiotherapie Marie Curie, Arras, France
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2015-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 90
- Registration Number
- NCT01135498
© Copyright 2025. All Rights Reserved by MedPath